Lupin signs distribution agreement with scope Ophthalmics for eye care products in Mexico

Lupin to distribute OPTASE range, addressing dry eyes and related conditions in Mexican market

Global pharma major Lupin today announced that it has signed a distribution agreement with Scope Ophthalmics Ireland (SCOPE) for the registration and marketing of a Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the OPTASE range, in Mexico.

The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions such as Dry Eyes, Blepharitis and Meibomian Gland Dysfunction (MGD). This eye care routine comprising of Heat, Cleanse, and Hydrate, follows the TFOS* Dry Eye management strategy, as outlined in the DEWS II** publication’s staged plan.

“We are very pleased to collaborate with SCOPE and integrate a part of their OPTASE® range of products into our Ophthalmology offerings. This expansion of our Ophthalmology range reinforces our commitment to enhancing vision care for our patients, improving their quality of life,” said Dr Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.

“Through the signature of this collaboration with Lupin, SCOPE is expanding its footprint in Latin America for its OPTASE range. Mexico is clearly a country of strategic importance for SCOPE where our innovative eyecare products, together with the strong relationships of Lupin amongst Eye Care Professionals as well as its overall credibility in the market, will certainly contribute to the success of both companies” said Tom Freyne, CEO at SCOPE.

BlepharitisDEWS IIeye care productsLupinMeibomian Gland DysfunctionMoist Heat MaskOPTASE rangeScope OphthalmicsTea Tree Oil Eyelid Cleansing GelTFOS Dry Eye strategy
Comments (1)
Add Comment
  • Brandon

    This distribution agreement between Lupin and Scope Ophthalmics is exciting news for the eye care market in Mexico! It’s great to see collaboration that can enhance access to quality eye care products. This partnership could significantly impact patient outcomes. Looking forward to seeing how this develops!